|
TST+ subjects without a past MTB exposure: trends of RD1 test during follow up in the responders* |
||||||
| Group of subjects analysed |
Number of subjects N (%) |
Time 1 0 months |
Time 2 1–2 months |
Time 3 6 months |
Time 2 vs time 1 |
Time 3 vs time 1 |
|
|
||||||
| IFN-gamma (IU/ml) |
||||||
|
|
||||||
| No INH |
6 (100) |
|||||
| PHA |
6 (100) |
9.9 ± 4.3 |
8.6 ± 4.1 |
12.1 ± 6.5 |
Ns |
Ns |
| PPD |
6 (100) |
27.4 ± 3.1 |
21.4 ± 4.9 |
23.5 ± 3.8 |
Ns |
Ns |
| QTF-G |
6 (100) |
21.1 ± 5.2 |
19.5 ± 7.2 |
20.2 ± 6.1 |
Ns |
Ns |
| RD1 proteins |
6 (100) |
16.1 ± 4.5 |
16.3 ± 7.2 |
7.3 ± 2.2 |
Ns |
Ns |
| RD1 peptides |
6 (100) |
7.5 ± 3.3 |
7.0 ± 4.7 |
5.7 ± 4 |
Ns |
Ns |
| INH therapy |
24 (100) |
|||||
| PHA |
24 (100) |
14.7 ± 2.7 |
16.8 ± 3 |
14.8 ± 2.8 |
Ns |
Ns |
| PPD |
24 (100) |
17.6 ± 2.8 |
15.6 ± 2.7 |
14.1 ± 2.5 |
Ns |
Ns |
| QTF-G |
19 (79) |
17.5 ± 2.7 |
11.6 ± 2.5 |
5.2 ± 1.3 |
p = 0.03 |
p = 0.0001 |
| RD1 proteins |
18 (75) |
12.5 ± 2.6 |
5.4 ± 1.4 |
2.6 ± 0.9 |
p = 0.001 |
p = 0.0002 |
| RD1 peptides |
15 (63) |
9.2 ± 1.7 |
3.4 ± 0.9 |
0.9 ± 0.1 |
p = 0.005 |
p = 0.0005 |
|
*Responders are defined as those responding to the tests at baseline. T1: time 1 (baseline); T2. time 2 (after 1–2 months INH therapy), T3: time 3 (after 6 months, at therapy completion). IFN: interferon; PHA: Phytohemagglutinin; PPD: purified protein derivative; RD: region of difference; QTF-G: QuantiFERON TB Gold; IFN: interferon; IU: international units. INH: isoniazid; ns: not statistically significant. | ||||||
Goletti et al. Respiratory Research 2007 8:5 doi:10.1186/1465-9921-8-5 |
||||||